News | November 07, 2022
Balaxi Pharmaceuticals delivers strong growth in Q2 FY23
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community
Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US
Sildenafil for Oral Suspension (RLD Revatio) had estimated annual sales of US $64 million in the US
Subscribe To Our Newsletter & Stay Updated
